Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL

Peter Hillmen • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia Acalabrutinib Ibrutinib

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukemia (CLL) cells and the common side-effects experienced by these drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

More from Peter Hillmen

Key updates from the interim analysis of the FLAIR trial 1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
CLL trial updates from EHA 2022 1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL 1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
The role of MRD in decision-making in CLL 1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 1:45
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman • 7 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals